Stockreport

MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024

MDxHealth SA - Ordinary Shares  (MDXH) 
PDF Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma [Read more]